---
category: news
title: "BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights"
excerpt: "Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Top-line data readout in Q4 2022/early Q1 2023 for TRANQUILITY II Phase 3 trial evaluating BXCL501 in acute treatment of agitation associated with Alzheimer’s disease Extended cash runway into 2025 with $260 million strategic financing for IGALMI commercial launch and clinical and regulatory milestones U."
publishedDateTime: 2022-05-09T11:03:00Z
originalUrl: "https://apnews.com/press-release/globe-newswire/covid-technology-health-business-mental-3717bf59c739265c231f90dcf287f725"
webUrl: "https://apnews.com/press-release/globe-newswire/covid-technology-health-business-mental-3717bf59c739265c231f90dcf287f725"
type: article
quality: 10
heat: 10
published: false

provider:
  name: Associated Press
  domain: apnews.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://apnews.com/images/PaidContent3.png"
    width: 700
    height: 450
    isCached: true

secured: "lmVejGotolj4JXGhv7KSls37Ix7bCahSeMRCwiccBxHgL31rsy5PSvBVZFrPwNwoXpmt9ueeHYfNsDZj1ZUocaaBqhsjSdiUJhxrhqP3gGGubZWug0rDUm6yBh/dTACPxP9S1WsptwO0yQUspmB+NlxXTVNHlLwdI0G36oDGavlHXPFFRgSt3oy5MbEQz71JSmj0GFibAK3A7780NM7I3luwH0vtLBSWfyZaYxTfDkjNmTCgJDhEiyfx636Jbqem1+tso2oGXsh81sb56FvFQVPp0hMPrPMba+LKzOlla8I4UUmI97G3JB+gJuKwdPxsAlMgZIUtBMhAypjnrcsKxuFkzCflDPWnOxdsy+7H/2E=;1pGC73VlyaGx1HmCwwb70Q=="
---

